IMAX (IMAX) Could Be 10% Undervalued On Odyssey Buzz And Theater Expansion

Christopher Nolan’s The Odyssey is back in select IMAX (IMAX) theaters for a limited run, putting the premium large format in the spotlight just as a new Georgia Theatre Company partnership expands the network.

IMAX shares trade at US$50.80 after a small pullback in the past week and month. However, the 90 day share price return of 31.98% and 1 year total shareholder return of 63.40% point to momentum that has been building rather than fading.

Scan for other premium cinema and entertainment stocks showing similar momentum by checking our hand picked 20 high quality undiscovered gems alongside IMAX’s renewed spotlight.

After a 3 year total return that is already very large and a 1 year gain of 63.40%, IMAX now raises a simple question: Does the current price still leave enough potential upside to justify taking on new risk?

Most Popular Narrative: 10.4% Undervalued

IMAX closed at $50.80 while the most followed narrative pegs fair value closer to $56.68, so the story centers on whether the network and content pipeline can support that kind of gap.

The main thing that has to go right is that IMAX continues to convert its underpenetrated screen opportunity, strong box office titles such as The Odyssey, and growing local language and alternative content into sustained high incremental margins and recurring free cash flow.

See why 9 investors see IMAX as 10% undervalued.

Result: Fair Value of $56.68 (UNDERVALUED)

Still, the IMAX story can break if a softer blockbuster slate drags on box office, or if at home entertainment pulls more viewers away from cinemas.

Find out about the key risks to this IMAX narrative.

Another View: IMAX Through The P/E Lens

IMAX might look 10.4% undervalued against a US$56.68 fair value from the most popular narrative, yet the earnings multiple tells a tougher story. The shares trade on a P/E of 68.1x compared with 21.6x for the US Entertainment group, peers at 46.6x, and a fair ratio of 20.7x. That gap points to meaningful valuation risk if expectations cool, so how comfortable are you paying more than three times the fair ratio for this growth path?

See what the numbers say about this price in our valuation breakdown with See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With IMAX drawing strong opinions in both directions, do not wait for consensus to form. Weigh the trade off yourself by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond IMAX?

If IMAX has you thinking harder about pricing and momentum, do not stop there. Use the Simply Wall St screener to quickly spot other opportunities that fit your style.

• Target resilient compounders that pair quality with sensible pricing by scanning our 29 high quality undervalued stocks for ideas that might deserve a closer look.
• Strengthen your income stream by focusing on companies that prioritize reliable cash returns through our curated 8 dividend fortresses.
• Guard against surprises by concentrating on financially sound businesses using the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com